Walters Magdalene K, Bulterys Michelle, Barry Michael, Louden Diana, Hicks Sarah, Richey Ann, Sabin Margalit, Mahy Mary, Stover John, Glaubius Robert, Kyu Hmwe, Boily Marie-Claude, Mofenson Lynne, Powis Kathleen, Imai-Eaton Jeffrey
Imperial College London.
University of Washington.
medRxiv. 2024 Dec 5:2024.12.03.24318418. doi: 10.1101/2024.12.03.24318418.
Eliminating HIV vertical transmission (VT) and is a global priority. Estimates of paediatric HIV infections are commonly derived through mathematical models relying on rates of VT stratified by maternal immunological and treatment status from literature, namely the UNAIDS-supported Spectrum AIDS Impact Module (Spectrum-AIM) to assess progress towards eliminating VT. Default VT probabilities were last updated in 2018, since then there have been substantial changes to service delivery and ART regimens.
We aimed to (1) update the systematic review of VT probabilities by maternal status compatible with Spectrum-AIM, (2) conduct a meta-regression to systematically pool studies to estimate VT probabilities with statistical uncertainty, and (3) assess determinants of VT, including maternal viral load. We searched PubMed, Embase, Global Health Database, WHO Global Index Medicus, CINAHL Complete, and Cochrane CENTRAL for peer-reviewed articles in English from all geographic regions with data on VT from randomized controlled trials, cohort studies, or observational studies. We excluded sources that did not stratify VT by maternal treatment or immunological status. We fit four meta-regression models to produce VT probability estimates compatible with stratifications used in Spectrum-AIM and assessed how updated VT probabilities estimated new paediatric infections compared to default parameters in Spectrum-AIM. We conducted subgroup analyses to assess how study inclusion affected model estimates. Finally, we fit a meta-regression model to assess ART class and initiation timing on viral load suppression at delivery.
The updated systematic review identified 24 new studies published between January 2018 and February 2024. Combined with previous review data, 110 studies were included in the meta-regression analysis. Estimates were broadly consistent with previous reviews. For women not receiving PMTCT, the odds of perinatal transmission decreased by 0.20 (0.16-0.25) for each 100 mm increase in median CD4 of the study population. Among women on ART during pregnancy, each additional week on ART before delivery reduced the odds of VT by 5.6% (4.3%-6.8%). ART regimen class affected VT probability; the odds ratio of perinatal VT among WLHIV who initiated an INSTI-based regimen versus a NNRTI-based regimen 20 weeks before delivery was 0.355 (0.140-0.898). However, this effect was confounded by study region. Viral load suppression at delivery was significantly lower among women who started ART late during pregnancy (p=0.02), but did not significantly differ by ART class (p>0.05).
Vertical transmission rates vary substantially according to maternal immunological stage, prophylactic regimen, and timing of treatment initiation. Time of initiation on ART before delivery was strongly associated with viral load suppression at delivery. Our estimates and their uncertainty can be used in Spectrum-AIM to produce estimates of paediatric incidence to inform funding and monitor progress towards eliminating VT.
National Institutes of Health, UNAIDS, and the Medical Research Council.
消除艾滋病毒垂直传播是一项全球优先事项。儿科艾滋病毒感染的估计通常通过数学模型得出,这些模型依赖于文献中按孕产妇免疫和治疗状况分层的垂直传播率,即联合国艾滋病规划署支持的“频谱艾滋病影响模块”(Spectrum - AIM)来评估在消除垂直传播方面取得的进展。默认的垂直传播概率上次更新于2018年,自那时以来,服务提供和抗逆转录病毒治疗方案发生了重大变化。
我们旨在(1)更新与Spectrum - AIM兼容的按孕产妇状况进行的垂直传播概率系统评价,(2)进行meta回归以系统汇总研究,估计具有统计不确定性的垂直传播概率,以及(3)评估垂直传播的决定因素,包括孕产妇病毒载量。我们在PubMed、Embase、全球卫生数据库、世界卫生组织全球医学索引、CINAHL Complete和Cochrane CENTRAL中搜索了来自所有地理区域的英文同行评审文章,这些文章包含来自随机对照试验、队列研究或观察性研究的垂直传播数据。我们排除了未按孕产妇治疗或免疫状况对垂直传播进行分层的来源。我们拟合了四个meta回归模型,以产生与Spectrum - AIM中使用的分层兼容的垂直传播概率估计值,并评估更新后的垂直传播概率与Spectrum - AIM中的默认参数相比如何估计新的儿科感染情况。我们进行了亚组分析,以评估研究纳入如何影响模型估计。最后,我们拟合了一个meta回归模型,以评估抗逆转录病毒治疗类别和开始时间对分娩时病毒载量抑制的影响。
更新后的系统评价确定了2018年1月至2024年2月期间发表的24项新研究。结合先前的综述数据,110项研究纳入了meta回归分析。估计结果与先前的综述大致一致。对于未接受预防母婴传播的妇女,研究人群的CD4中位数每增加100个/mm,围产期传播几率降低0.20(0.16 - 0.25)。在孕期接受抗逆转录病毒治疗的妇女中,分娩前每多接受一周抗逆转录病毒治疗,垂直传播几率降低5.6%(4.3% - 6.8%)。抗逆转录病毒治疗方案类别影响垂直传播概率;在分娩前20周开始基于整合酶链转移抑制剂(INSTI)方案而非基于非核苷类逆转录酶抑制剂(NNRTI)方案的感染艾滋病毒的妇女中,围产期垂直传播的优势比为0.355(0.140 - 0.898)。然而,这种效应因研究地区而混淆。孕期开始抗逆转录病毒治疗较晚的妇女分娩时的病毒载量抑制显著较低(p = 0.02),但不同抗逆转录病毒治疗类别之间无显著差异(p>0.05)。
垂直传播率根据孕产妇免疫阶段、预防方案和治疗开始时间有很大差异。分娩前开始抗逆转录病毒治疗的时间与分娩时的病毒载量抑制密切相关。我们的估计及其不确定性可用于Spectrum - AIM中,以产生儿科发病率估计值,为资金提供信息并监测在消除垂直传播方面的进展。
美国国立卫生研究院、联合国艾滋病规划署和医学研究理事会。